- 16Volume 3, 2020Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
Agenus Provides R&D Update & Second Quarter Financial Report investor.agenusbio.com/2020-08-06-Age…
Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the William Blair Biotech Focus 2020 Conference investor.agenusbio.com/2020-08-04-Age…
$AGEN R&D update & 2Q Earnings: - Registration plans for bal +/- zali - $AGEN/Betta partnership - AGEN1181 +/- bal (anti-PD-1) - iNKT cells for COVID-19 & cancer - AGEN1223 & AGEN2373 update - Myeloid cell targets (TIGIT(s)/novel) investor.agenusbio.com/2020-07-29-Age…
Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals investor.agenusbio.com/press-releases…
AGENUS NEWSLETTER: The immune system is complex. $AGEN's portfolio is designed to empower the body’s immune system to do its job – to cure disease. READ MORE: agenusbio.com/wp-content/upl…
$AGEN files new shelf registration statement as current shelf nears expiry. sec.gov/Archives/edgar…
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit investor.agenusbio.com/2020-07-21-Age…
$AGEN optimal combos with allogeneic cell therapy (iNKT), checkpoint antibodies for cures in preclinical models resistant to anti-PD-1. @Agenus_Bio is well-positioned to deliver these combos from our proprietary pipeline. #AACR2020 #Cancer agenusbio.com/publications/#… twitter.com/Agenus_Bio/sta… Retweeted by Agenus Inc. ($AGEN)
At #AACR2020, $AGEN demonstrated potential for curative combinations with #celltherapy & #Checkpoint antibodies in models refractory to anti-PD-1. @Agenus_Bio proprietary pipeline is positioned to deliver these combos! #Immunotherapy #cancer
At #AACR2020 we @Agenus_Bio demonstrate the curative combination potential of our pipeline in models that are refractory to first generation IO therapies. $AGEN is best positioned to advance more effective combinations for cancer patients today. twitter.com/Agenus_Bio/sta… Retweeted by Agenus Inc. ($AGEN)
$AGEN Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020 investor.agenusbio.com/2020-06-22-Age…
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China investor.agenusbio.com/2020-06-22-Age…
@Agentus_CellTX CEO Walter Flamenbaum & CTO Marc Van Dijk reveal proprietary allogeneic iNKTs have potential to treat solid tumors with antibody combos (with $AGEN CPIs) affordably. iNKTs are advancing in #COVID19 & #Cancer @RaymondJames #Healthcare conference Retweeted by Agenus Inc. ($AGEN)
Experts Drs. Marc Van Dijk & Walter Flamenbaum join cell therapy expert panel @RaymondJames Conference: #CellTherapy: Promise of the Next Generation.
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408. Retweeted by Agenus Inc. ($AGEN)
NEWSLETTER: #ASCO20 highlights and $AGEN pipeline of Fc engineered TIGIT & CTLA-4 with our plans to unlock value for patients with #Cancer agenusbio.com/wp-content/upl…
TUNE IN: Shoptalk Virtual Conference with @garo_armen Chairman and CEO at @Agenus_Bio, to discuss the future of retail based on progress in COVID-19 therapeutics and vaccines on June 11 1-1:45pm ET. twitter.com/shoptalk/statu…
Register now at https://t.co/Aoo8WQKgL7
— Shoptalk (@shoptalk) June 8, 2020
Don't miss our next Shoptalk Virtual Conference on Thu, June 11 from 1-1:45 pm ET. Our interview with @garo_armen, Chairman and CEO at @Agenus_Bio, will explore the future of retail based on progress in COVID-19 therapeutics and vaccines. pic.twitter.com/Y4hq9pFyzp
FDA clears IND application for natural killer T-cell therapy @Agenus_Bio @Agentus_CellTX to treat #COVID19 - phase 1 trial to come bit.ly/2Ax2Rwscome bit.ly/2 Retweeted by Agenus Inc. ($AGEN)
FBR has informed callers to use 973-413-6102 twitter.com/Agenus_Bio/sta…
EXPERT PANEL TONIGHT! Join Dr. Steven @ODayMD @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial #innovation #nextgeneration pic.twitter.com/omgnBDFffg
— Agenus Inc. ($AGEN) (@Agenus_Bio) June 2, 2020